Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative age effect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    642 result(s) found for: Relative age effect. Displaying page 6 of 33.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2017-001878-42 Sponsor Protocol Number: viagra01 Start Date*: 2018-03-27
    Sponsor Name:CONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA
    Full Title: Sildenafil Citrate effect on in vivo human trophoblast research.
    Medical condition: This is a placebo – controlled longitudinal study to determine whether maternal administration of an unique oral dose of sildenafil citrate (50mg) improves placental flow in first trimester in ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036585 Pregnancy, puerperium and perinatal conditions SOC
    20.0 100000004869 10036569 Pregnancy related circumstances HLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006170-28 Sponsor Protocol Number: E2007-G000-307 Start Date*: 2008-09-15
    Sponsor Name:Eisai Ltd
    Full Title: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy i...
    Medical condition: Epilepsy: refractory partial seizures with or without secondary generalisation
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) AT (Completed) BE (Completed) PT (Completed) LT (Completed) NL (Completed) HU (Completed) FR (Completed) GB (Completed) SE (Completed) EE (Completed) LV (Completed) DK (Completed) IT (Completed) DE (Completed) FI (Completed) BG (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-006130-16 Sponsor Protocol Number: EFFECTS2012 Start Date*: 2014-08-08
    Sponsor Name:Karolinska Institutet
    Full Title: ESTABLISHING THE EFFECT(S) AND SAFETY OF FLUOXETINE INITIATED IN THE ACUTE PHASE OF STROKE
    Medical condition: Cerebrovascular diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000501-23 Sponsor Protocol Number: B7451014 Start Date*: 2018-10-16
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to seve...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) NL (Completed) BE (Completed) PL (Completed) DE (Completed) LV (Completed) SK (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-004271-14 Sponsor Protocol Number: DAPAS Start Date*: 2021-12-06
    Sponsor Name:Aarhus University Hospital, department of Cardiology
    Full Title: Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis intervention
    Medical condition: Patients with aortic stenosis undergoing trans catheter aortic valve replacement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10058186 Aortic valve stenosis and insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003714-68 Sponsor Protocol Number: 1744/2017 Start Date*: 2017-11-15
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A prospective randomized clinical trial
    Medical condition: Evaluation of the effect of 80% versus 30% supplemental oxygen administration during major abdominal surgery on postoperative brain natriuretic peptide concentration.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059883 Fraction of inspired oxygen PT
    20.0 100000173317 10050322 Oxygen supplementation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005575-17 Sponsor Protocol Number: 3082B2-313-WW Start Date*: 2008-04-07
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Child...
    Medical condition: Younger Male Haemophilia A patients < 6 years of age with moderately severe to severe hemophilia A (FVIII activity =< 2%), with previous FVIII replacement therapy experience (>=50 exposure days). ...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: ES (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000634-33 Sponsor Protocol Number: D967SC00001 Start Date*: 2021-11-02
    Sponsor Name:ASTRAZENECA AB
    Full Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harb...
    Medical condition: Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084787 HER2 mutant non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004175-12 Sponsor Protocol Number: B7931028 Start Date*: 2019-10-01
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) RO (Completed) BG (Completed) PT (Completed) DE (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003234-82 Sponsor Protocol Number: NTMT-03-A Start Date*: 2018-06-13
    Sponsor Name:Neurotech Pharmaceuticals
    Full Title: A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia type 2
    Medical condition: Macular Telangiectasia type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002533-32 Sponsor Protocol Number: INS1007-201 Start Date*: 2018-03-22
    Sponsor Name:Insmed Incorporated
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 We...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) SE (Completed) ES (Completed) NL (Completed) BG (Completed) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005136-30 Sponsor Protocol Number: MK-6024-001 Start Date*: 2021-08-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease
    Medical condition: Nonalcoholic Fatty Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10082249 Nonalcoholic fatty liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004125-32 Sponsor Protocol Number: APOCT-004 Start Date*: 2018-03-28
    Sponsor Name:Apodemus Aktiebolag
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the safety, efficacy and pharmakokinetics of Pleconaril as an add on to AchEI/memantine for treatment of patients with Alzheimer’s d...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002318-22 Sponsor Protocol Number: CTBM100C2303 Start Date*: 2009-09-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a ...
    Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-004023-31 Sponsor Protocol Number: LPS-Fluenz Start Date*: 2016-01-06
    Sponsor Name:Radboudumc
    Full Title: The effects of endotoxin challenge on the immune response elicited by a subsequent challenge with Fluenz™ in healthy volunteers, a pilot study
    Medical condition: Inflammatory conditions in general and immunosuppressive conditions is particular
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000847-16 Sponsor Protocol Number: D1532C00057 Start Date*: 2019-01-29
    Sponsor Name:National Cancer Institute, Cancer Therapy Evaluation Program
    Full Title: A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, ARRY-142886, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable...
    Medical condition: Neurofibromatosis type 1 (NF1)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029267 Neurofibroma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-017136-40 Sponsor Protocol Number: 28431754DIA3004 Start Date*: 2010-03-25
    Sponsor Name:Janssen - Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the...
    Medical condition: Type 2 Diabetes Mellitus with Moderate Renal Impairment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    12.1 10062237 Renal impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) DE (Completed) FR (Completed) IT (Prematurely Ended) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002184-17 Sponsor Protocol Number: TRA115450 Start Date*: 2012-02-08
    Sponsor Name:Glaxosmithkline Research and Development Ltd
    Full Title: A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pa...
    Medical condition: To assess the efficacy of eltrombopag, relative to placebo, in achieving platelet counts of ≥ 50 Gi/L, when administered to pediatric subjects with previously treated chronic ITP during the first 1...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002843-18 Sponsor Protocol Number: AS3201-G000-291 Start Date*: 2009-09-21
    Sponsor Name:Eisai Limited
    Full Title: A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimo...
    Medical condition: Diabetic Sensorimotor Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012685 Diabetic polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) EE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003827-37 Sponsor Protocol Number: 20110109 Start Date*: 2012-01-06
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-term Tolerability and Durable Efficacy of AMG 145 on LDL-C in Hyperlipidemic Subjects
    Medical condition: Hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: CZ (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 17:23:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA